Similar articles for PMID: 22843749

Year	Number of Results
1968	1
2002	1
2004	1
2005	4
2006	4
2007	7
2008	14
2009	11
2010	13
2011	16
2012	16
2013	18
2014	13
2015	3
2018	1
2019	1
2020	1
2021	1
2024	0

1

A rare but severe pulmonary side effect of cetuximab in two patients.

Achermann Y, Frauenfelder T, Obrist S, Zaugg K, Corti N, Günthard HF. Achermann Y, et al. BMJ Case Rep. 2012 Jul 25;2012:bcr0320125973. doi: 10.1136/bcr-03-2012-5973. BMJ Case Rep. 2012. PMID: 22843749 Free PMC article. Review.

2

A case of fatal cetuximab-induced interstitial lung disease during the first weeks of treatment.

Shablak A, Conn A. Shablak A, et al. Target Oncol. 2014 Jun;9(2):177-80. doi: 10.1007/s11523-013-0295-4. Epub 2013 Oct 10. Target Oncol. 2014. PMID: 24114566

3

Severe infusion reactions to cetuximab occur within 1 h in patients with metastatic colorectal cancer: results of a nationwide, multicenter, prospective registry study of 2126 patients in Japan.

Yamaguchi K, Watanabe T, Satoh T, Ishiguro M, Izawa M, Inoshiri S, Sugihara K, Sakata Y. Yamaguchi K, et al. Jpn J Clin Oncol. 2014 Jun;44(6):541-6. doi: 10.1093/jjco/hyu049. Epub 2014 Apr 24. Jpn J Clin Oncol. 2014. PMID: 24771864 Free PMC article.

4

[Anti-epidermal growth factor receptor monoclonal antibodies induced adverse events].

Tsuji Y, Kogawa T, Abe M. Tsuji Y, et al. Gan To Kagaku Ryoho. 2010 May;37(5):787-90. Gan To Kagaku Ryoho. 2010. PMID: 20495307 Japanese.

5

A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions.

Maier S, Chung CH, Morse M, Platts-Mills T, Townes L, Mukhopadhyay P, Bhagavatheeswaran P, Racenberg J, Trifan OC. Maier S, et al. Cancer Med. 2015 Jan;4(1):36-42. doi: 10.1002/cam4.333. Epub 2014 Oct 9. Cancer Med. 2015. PMID: 25296628 Free PMC article.

6

Acute interstitial pneumonitis in a patient receiving a FOLFOX-4 regimen plus cetuximab treated with pulse therapy.

Lai JI, Wang WS, Lai YC, Lin PC, Chang SC. Lai JI, et al. Int J Clin Pharmacol Ther. 2010 Jul;48(7):425-8. doi: 10.5414/cpp48425. Int J Clin Pharmacol Ther. 2010. PMID: 20557834

7

Hypersensitivity and tumor lysis syndrome associated with cetuximab treatment: should we be afraid?

Cihan S, Atasoy A, Yildirim Y, Babacan NA, Kos TF. Cihan S, et al. Tumori. 2015 Apr 28;101(2):e40-5. doi: 10.5301/tj.5000246. Tumori. 2015. PMID: 25721679

8

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.

Harding J, Burtness B. Harding J, et al. Drugs Today (Barc). 2005 Feb;41(2):107-27. doi: 10.1358/dot.2005.41.2.882662. Drugs Today (Barc). 2005. PMID: 15821783 Review.

9

Cetuximab infusion reactions: French pharmacovigilance database analysis.

Grandvuillemin A, Disson-Dautriche A, Miremont-Salamé G, Fourrier-Reglat A, Sgro C; Réseau des Centres Régionaux de Pharmacovigilance Français. Grandvuillemin A, et al. J Oncol Pharm Pract. 2013 Jun;19(2):130-7. doi: 10.1177/1078155212457965. Epub 2012 Nov 15. J Oncol Pharm Pract. 2013. PMID: 23154574

10

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma.

Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, Temel JS, Schrag D, Bhargava P, Meyerhardt JA, Wolpin BM, Fidias P, Zheng H, Florio S, Regan E, Fuchs CS. Chan JA, et al. Ann Oncol. 2011 Jun;22(6):1367-1373. doi: 10.1093/annonc/mdq604. Epub 2011 Jan 7. Ann Oncol. 2011. PMID: 21217058 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year